

David T W Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3370723/publications.pdf>

Version: 2024-02-01

267
papers

50,632
citations

2671

95
h-index

1713

213
g-index

285
all docs

285
docs citations

285
times ranked

44955
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	13.7	8,060
2	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.	13.7	2,129
3	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	13.7	1,872
4	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	7.7	1,551
5	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
6	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	7.7	933
7	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	3.9	863
8	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
9	Tandem Duplication Producing a Novel Oncogenic <i>BRAF</i> Fusion Gene Defines the Majority of Pilocytic Astrocytomas. <i>Cancer Research</i> , 2008, 68, 8673-8677.	0.4	786
10	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	13.7	765
11	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761
12	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	13.5	743
13	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	7.7	716
14	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	13.5	702
15	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <i>Nature</i> , 2012, 488, 106-110.	13.7	675
16	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	9.4	674
17	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. <i>Cancer Cell</i> , 2013, 24, 660-672.	7.7	633
18	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627

#	ARTICLE	IF	CITATIONS
19	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	5.1	586
20	Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , 2012, 12, 818-834.	12.8	560
21	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540
22	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	13.7	521
23	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
24	IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. <i>Neuro-Oncology</i> , 2009, 11, 341-347.	0.6	504
25	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	7.7	494
26	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	12.8	469
27	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438
28	Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. <i>Nature Genetics</i> , 2020, 52, 331-341.	9.4	431
29	Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	0.8	381
30	Recurrent somatic mutations in <i>ACVR1</i> in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.	9.4	381
31	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <i>Nature</i> , 2014, 510, 537-541.	13.7	378
32	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	3.9	378
33	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. <i>Acta Neuropathologica</i> , 2012, 124, 615-625.	3.9	376
34	Pilocytic astrocytoma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 775-788.	3.9	328
35	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. <i>Acta Neuropathologica</i> , 2013, 125, 651-658.	3.9	324
36	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	13.7	318

#	ARTICLE	IF	CITATIONS
37	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1011-1022.	5.1	315
38	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210.	3.9	308
39	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
40	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	3.9	298
41	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	3.9	277
42	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
43	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. <i>Acta Neuropathologica</i> , 2014, 128, 551-559.	3.9	268
44	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	5.1	268
45	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. <i>Nature Communications</i> , 2015, 6, 10001.	5.8	266
46	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266
47	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
48	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
49	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	3.9	254
50	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. <i>Acta Neuropathologica</i> , 2013, 125, 659-669.	3.9	250
51	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
52	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	3.9	244
53	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. <i>Nature Communications</i> , 2015, 6, 7391.	5.8	244
54	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015, 130, 407-417.	3.9	237

#	ARTICLE	IF	CITATIONS
55	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
56	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. <i>Journal of Clinical Oncology</i> , 2017, 35, 2370-2377.	0.8	223
57	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
58	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. <i>Lancet Oncology</i> , The, 2013, 14, 534-542.	5.1	212
59	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774.	3.9	211
60	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. <i>Acta Neuropathologica</i> , 2013, 125, 351-358.	3.9	208
61	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	3.9	203
62	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , 2018, 136, 211-226.	3.9	199
63	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependyoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	3.9	191
64	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291.	3.9	190
65	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. <i>Nature Medicine</i> , 2016, 22, 1314-1320.	15.2	183
66	MAPK pathway activation in pilocytic astrocytoma. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1799-1811.	2.4	177
67	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	3.9	176
68	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1408-1416.	0.6	175
69	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. <i>Acta Neuropathologica</i> , 2017, 133, 417-429.	3.9	172
70	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	13.7	170
71	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857.	0.6	170
72	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. <i>Acta Neuropathologica</i> , 2019, 137, 683-687.	3.9	170

#	ARTICLE	IF	CITATIONS
73	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	3.9	169
74	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. <i>Acta Neuropathologica</i> , 2016, 131, 137-146.	3.9	162
75	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
76	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
77	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. <i>Acta Neuropathologica</i> , 2017, 133, 431-444.	3.9	155
78	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. <i>Acta Neuropathologica</i> , 2016, 131, 877-887.	3.9	151
79	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	5.1	151
80	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
81	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	3.9	144
82	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. <i>Cancer Cell</i> , 2018, 33, 829-842.e5.	7.7	140
83	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. <i>Acta Neuropathologica Communications</i> , 2016, 4, 20.	2.4	136
84	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. <i>Clinical Cancer Research</i> , 2011, 17, 4650-4660.	3.2	135
85	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. <i>Acta Neuropathologica</i> , 2016, 132, 149-151.	3.9	127
86	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. <i>Acta Neuropathologica</i> , 2014, 128, 137-149.	3.9	125
87	A biobank of patient-derived pediatric brain tumor models. <i>Nature Medicine</i> , 2018, 24, 1752-1761.	15.2	124
88	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. <i>Nature Communications</i> , 2017, 8, 14758.	5.8	118
89	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	3.9	118
90	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	0.6	116

#	ARTICLE	IF	CITATIONS
91	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	3.9	116
92	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). <i>Acta Neuropathologica</i> , 2012, 124, 875-881.	3.9	115
93	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	9.4	112
94	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	7.7	110
95	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	3.9	104
96	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	3.9	104
97	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. <i>Acta Neuropathologica</i> , 2020, 139, 1109-1113.	3.9	104
98	Nuclear relocation of <i>STAT6</i> reliably predicts <i>NAB2</i> - <i>STAT6</i> fusion for the diagnosis of solitary fibrous tumour. <i>Histopathology</i> , 2014, 65, 613-622.	1.6	101
99	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. <i>Acta Neuropathologica Communications</i> , 2019, 7, 24.	2.4	101
100	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	0.6	100
101	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98
102	Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. <i>Nucleic Acids Research</i> , 2015, 43, e10-e10.	6.5	95
103	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	13.7	94
104	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
105	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	13.5	93
106	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	0.8	93
107	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662.	2.1	89
108	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. <i>Nature Protocols</i> , 2020, 15, 479-512.	5.5	89

#	ARTICLE	IF	CITATIONS
109	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. <i>Acta Neuropathologica</i> , 2013, 126, 757-762.	3.9	88
110	Genomic footprints of activated telomere maintenance mechanisms in cancer. <i>Nature Communications</i> , 2020, 11, 733.	5.8	87
111	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2013, 126, 291-301.	3.9	84
112	Transcriptomic and epigenetic profiling of "diffuse midline gliomas, H3 K27M-mutant" discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. <i>Acta Neuropathologica Communications</i> , 2018, 6, 117.	2.4	83
113	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	3.9	83
114	<i>MGMT</i> CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with <i>IDH1</i> or <i>IDH2</i> mutations. <i>International Journal of Cancer</i> , 2012, 131, 1104-1113.	2.3	78
115	Assessing CpG island methylator phenotype, 1p/19q codeletion, and <i>MGMT</i> promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638.	0.6	77
116	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256.	2.9	76
117	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43.	0.6	75
118	Gliomatosis cerebri: no evidence for a separate brain tumor entity. <i>Acta Neuropathologica</i> , 2016, 131, 309-319.	3.9	74
119	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308.	3.9	74
120	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
121	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637.	3.9	73
122	Super enhancers define regulatory subtypes and cell identity in neuroblastoma. <i>Nature Cancer</i> , 2021, 2, 114-128.	5.7	73
123	Genomic Analysis of Pilocytic Astrocytomas at 0.97 Mb Resolution Shows an Increasing Tendency Toward Chromosomal Copy Number Change With Age. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1049-1058.	0.9	72
124	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. <i>Lancet Oncology</i> , The, 2015, 16, e293-e302.	5.1	72
125	Recurrent intragenic rearrangements of <i>EGFR</i> and <i>BRAF</i> in soft tissue tumors of infants. <i>Nature Communications</i> , 2018, 9, 2378.	5.8	72
126	Response to trametinib treatment in progressive pediatric low-grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 499-510.	1.4	68

#	ARTICLE	IF	CITATIONS
127	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 1344-1348.	3.9	68
128	Hypermethylation of the Inactive X Chromosome Is a Frequent Event in Cancer. <i>Cell</i> , 2013, 155, 567-581.	13.5	67
129	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	0.6	67
130	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	3.9	66
131	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. <i>Brain Pathology</i> , 2015, 25, 202-208.	2.1	66
132	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. <i>Nature Communications</i> , 2018, 9, 4760.	5.8	66
133	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	0.6	65
134	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3914.	5.8	65
135	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	7.7	65
136	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. <i>Oncotarget</i> , 2016, 7, 28169-28182.	0.8	62
137	<i>EWSR1</i> gene fusion may define a new glioneuronal tumor entity. <i>Brain Pathology</i> , 2019, 29, 53-62.	2.1	61
138	DNA methylation-based reclassification of olfactory neuroblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 255-271.	3.9	59
139	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	3.5	58
140	Cribiform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. <i>Brain Pathology</i> , 2017, 27, 411-418.	2.1	58
141	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	0.8	58
142	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in <i>FGFR1</i> , with recurrent co-mutation of <i>PIK3CA</i> and <i>NF1</i> . <i>Acta Neuropathologica</i> , 2019, 138, 497-504.	3.9	57
143	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , 2018, 20, 400-410.	0.6	56
144	<i>FGFR1:TACC1</i> fusion is a frequent event in molecularly defined extraventricular neurocytoma. <i>Acta Neuropathologica</i> , 2018, 136, 293-302.	3.9	56

#	ARTICLE	IF	CITATIONS
145	TelomereHunter – in silico estimation of telomere content and composition from cancer genomes. <i>BMC Bioinformatics</i> , 2019, 20, 272.	1.2	56
146	H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. <i>Cancer Cell</i> , 2021, 39, 407-422.e13.	7.7	56
147	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	3.2	55
148	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 121-130.	2.7	55
149	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. <i>Acta Neuropathologica</i> , 2014, 128, 123-136.	3.9	54
150	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. <i>Nature Communications</i> , 2018, 9, 2868.	5.8	54
151	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	3.9	52
152	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. <i>Clinical Sarcoma Research</i> , 2017, 7, 9.	2.3	51
153	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , 2019, 114, 27-35.	1.3	51
154	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2019, 137, 521-525.	3.9	51
155	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1–NFATc2 fusion from Ewing sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1273-1281.	1.2	50
156	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. <i>Acta Neuropathologica</i> , 2020, 139, 243-257.	3.9	50
157	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. <i>Leukemia</i> , 2017, 31, 2048-2056.	3.3	47
158	Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. <i>Acta Neuropathologica</i> , 2011, 121, 753-761.	3.9	46
159	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. <i>Nature Communications</i> , 2021, 12, 1269.	5.8	46
160	Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics. <i>Neuroscience</i> , 2014, 264, 171-185.	1.1	45
161	From class waivers to precision medicine in paediatric oncology. <i>Lancet Oncology</i> , The, 2017, 18, e394-e404.	5.1	45
162	YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218.	3.9	45

#	ARTICLE	IF	CITATIONS
163	Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581.	3.9	45
164	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44
165	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	3.9	44
166	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846.	3.9	43
167	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	0.8	43
168	Telomere dysfunction and chromothripsis. <i>International Journal of Cancer</i> , 2016, 138, 2905-2914.	2.3	42
169	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	1.4	42
170	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835.	3.9	42
171	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
172	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. <i>Brain Pathology</i> , 2016, 26, 199-205.	2.1	39
173	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. <i>Molecular Cancer Research</i> , 2018, 16, 1491-1498.	1.5	39
174	Droplet digital PCR is a powerful technique to demonstrate frequent <i>FGFR1</i> duplication in dysembryoplastic neuroepithelial tumors. <i>Oncotarget</i> , 2017, 8, 2104-2113.	0.8	39
175	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. <i>Neuropathology</i> , 2015, 35, 538-544.	0.7	38
176	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. <i>Acta Neuropathologica</i> , 2017, 134, 965-967.	3.9	38
177	The Role of Chromatin Remodeling in Medulloblastoma. <i>Brain Pathology</i> , 2013, 23, 193-199.	2.1	37
178	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	2.4	37
179	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. <i>Acta Neuropathologica</i> , 2018, 136, 339-343.	3.9	37
180	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019, 7, 163.	2.4	37

#	ARTICLE	IF	CITATIONS
181	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. <i>Acta Neuropathologica</i> , 2014, 128, 449-452.	3.9	36
182	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. <i>Neuro-Oncology</i> , 2018, 20, 1517-1524.	0.6	36
183	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). <i>Acta Neuropathologica</i> , 2021, 141, 605-617.	3.9	36
184	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	3.9	36
185	Arhgap36-dependent activation of Gli transcription factors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11061-11066.	3.3	35
186	Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 418-427.	1.5	34
187	EGFL7 enhances surface expression of integrin $\alpha_5\beta_1$ to promote angiogenesis in malignant brain tumors. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	33
188	Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	3.9	33
189	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , 2018, 20, 826-837.	0.6	32
190	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. <i>Neuro-Oncology</i> , 2019, 21, 214-221.	0.6	31
191	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in <i>SMARCE1</i> . <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	3.9	31
192	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 109-121.	1.4	30
193	<i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 827-836.	3.2	29
194	No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. <i>Human Genetics</i> , 2016, 135, 469-475.	1.8	29
195	Duplications of <i>KIAA1549</i> and <i>BRAF</i> screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for <i>KIAA1549</i> - <i>BRAF</i> fusion detection in pilocytic astrocytomas. <i>Modern Pathology</i> , 2018, 31, 1490-1501.	2.9	29
196	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct <i>DICER1</i> -associated subgroup. <i>Modern Pathology</i> , 2021, 34, 1558-1569.	2.9	28
197	A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC). <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 464-467.	1.8	27
198	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in <i>RELA</i> -positive ependymoma. <i>Oncotarget</i> , 2016, 7, 61860-61873.	0.8	27

#	ARTICLE	IF	CITATIONS
199	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	3.9	26
200	Multifocal nerve lesions and <i>LZTR1</i> germline mutations in segmental schwannomatosis. <i>Annals of Neurology</i> , 2016, 80, 625-628.	2.8	25
201	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1355-1363.	3.2	24
202	DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas. <i>Neuro-Oncology</i> , 2019, 21, 867-877.	0.6	24
203	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. <i>BMC Cancer</i> , 2020, 20, 523.	1.1	24
204	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	3.9	24
205	Radiation-induced gliomas represent H3-IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. <i>Nature Communications</i> , 2021, 12, 5530.	5.8	24
206	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. <i>Acta Neuropathologica</i> , 2020, 140, 765-776.	3.9	23
207	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 20.	2.4	23
208	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. <i>Annual Review of Genetics</i> , 2019, 53, 483-503.	3.2	22
209	Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases. <i>Acta Neuropathologica Communications</i> , 2020, 8, 95.	2.4	22
210	Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. <i>American Journal of Neuroradiology</i> , 2017, 38, 1892-1898.	1.2	21
211	Drivers underpinning the malignant transformation of giant cell tumour of bone. <i>Journal of Pathology</i> , 2020, 252, 433-440.	2.1	21
212	Genome-Wide Analysis of Subependymomas Shows Underlying Chromosomal Copy Number Changes Involving Chromosomes 6, 7, 8 and 14 in a Proportion of Cases. <i>Brain Pathology</i> , 2008, 18, 469-473.	2.1	20
213	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). <i>Acta Neuropathologica</i> , 2018, 136, 303-313.	3.9	20
214	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. <i>Nature Cancer</i> , 2022, 3, 994-1011.	5.7	20
215	Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. <i>Acta Neuropathologica</i> , 2022, 143, 609-612.	3.9	19
216	Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. <i>Acta Neuropathologica</i> , 2018, 136, 657-660.	3.9	18

#	ARTICLE	IF	CITATIONS
217	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. <i>Modern Pathology</i> , 2021, 34, 2122-2129.	2.9	17
218	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	3.9	16
219	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. <i>Methods</i> , 2017, 114, 60-73.	1.9	15
220	<i>BRAF</i> V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 96-96.	0.8	15
221	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	2.1	14
222	Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. <i>Molecular Oncology</i> , 2018, 12, 1219-1232.	2.1	14
223	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. <i>Oncotarget</i> , 2015, 6, 31844-31856.	0.8	14
224	Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 655-664.	0.9	13
225	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with <i>VSNL1</i> as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	3.9	13
226	Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. <i>Cancers</i> , 2022, 14, 849.	1.7	13
227	Gain of 12p encompassing <i>CCND2</i> is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327.	3.9	12
228	Accurate calling of <i>KIAA1549-BRAF</i> fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414.	1.8	12
229	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	2.4	12
230	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	3.9	11
231	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 753-763.	1.8	11
232	Connect Four with Glioblastoma Stem Cell Factors. <i>Cell</i> , 2014, 157, 525-527.	13.5	10
233	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. <i>Neuro-Oncology</i> , 2020, 22, 1327-1338.	0.6	10
234	Precision medicine in pediatric solid cancers. <i>Seminars in Cancer Biology</i> , 2022, 84, 214-227.	4.3	10

#	ARTICLE	IF	CITATIONS
235	EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts. <i>Scientific Reports</i> , 2016, 6, 29731.	1.6	9
236	confFuse: High-Confidence Fusion Gene Detection across Tumor Entities. <i>Frontiers in Genetics</i> , 2017, 8, 137.	1.1	9
237	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 753-763.	1.8	9
238	Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 151-158.	1.4	9
239	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015.	3.9	9
240	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. <i>Acta Neuropathologica</i> , 2020, 139, 403-406.	3.9	9
241	TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. <i>Oncotarget</i> , 2016, 7, 47918-47926.	0.8	9
242	The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 163-167.	0.8	8
243	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 152728.	1.0	8
244	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. <i>Cancers</i> , 2021, 13, 4476.	1.7	8
245	Unusual paediatric spinal myxopapillary ependymomas: Unique molecular entities or pathological variations on a theme?. <i>Journal of Clinical Neuroscience</i> , 2018, 50, 144-148.	0.8	7
246	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. <i>European Journal of Cancer</i> , 2020, 130, 168-181.	1.3	7
247	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585.	0.6	7
248	Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naïve esophageal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 104123-104135.	0.8	7
249	Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043.	3.9	7
250	Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1073-1075.	0.9	6
251	The age of adult pilocytic astrocytoma cells. <i>Oncogene</i> , 2021, 40, 2830-2841.	2.6	6
252	High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas. <i>Cancers</i> , 2021, 13, 3198.	1.7	6

#	ARTICLE	IF	CITATIONS
253	DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma. PLoS Computational Biology, 2021, 17, e1009562.	1.5	6
254	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. Acta Neuropathologica, 2020, 140, 237-239.	3.9	5
255	Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. Acta Neuropathologica, 2022, 144, 339-352.	3.9	5
256	<scp>P</scp>aired box gene 8 (<scp>PAX8</scp>) expression is associated with sonic hedgehog (<scp>SHH</scp>)/wingless int (<scp>WNT</scp>) subtypes, desmoplastic histology and patient survival in human medulloblastomas. Neuropathology and Applied Neurobiology, 2015, 41, 165-179.	1.8	4
257	The genomic landscape of pediatric renal cell carcinomas. IScience, 2022, 25, 104167.	1.9	3
258	Molecular progression of SHH-activated medulloblastomas. Acta Neuropathologica, 2019, 138, 327-330.	3.9	2
259	<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. JCO Precision Oncology, 2021, 5, 450-454.	1.5	2
260	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	1.4	2
261	MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. Biomarker Research, 2022, 10, .	2.8	2
262	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. BMC Proceedings, 2012, 6, .	1.8	1
263	Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK. Heliyon, 2018, 4, e01065.	1.4	1
264	Distinct DNA Methylation Patterns of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. Cellular and Molecular Neurobiology, 2022, 42, 2863-2892.	1.7	1
265	RAF Fusion Genes and MAPK Activation in Pilocytic Astrocytomas. , 2012, , 99-105.		0
266	Modern Principles of CNS Tumor Classification. , 2018, , 117-129.		0
267	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. Neuro-Oncology, 2022, 24, i81-i81.	0.6	0